Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ChemGenex Pharmaceuticals

Request full access

ChemGenex Pharmaceuticals Ltd, an integrated biopharmaceutical development company, engages in the discovery and the development of

Geelong, AustraliaFounded 1958Biotech & Life Sciences

About ChemGenex Pharmaceuticals

The story of Australian biopharmaceutical company ChemGenex is a classic tale of focusing on a core mission. Founded in 1999, the company, led by CEO and Managing Director Dr. Greg Collier, dedicated itself to developing treatments for cancer. The company's main focus became its lead product candidate, Omapro (omacetaxine), a treatment for patients with chronic myeloid leukemia. ChemGenex initially had a broader scope, also looking into metabolic diseases like diabetes and obesity. However, in 2007, the company made a strategic decision to restructure, demerging its metabolic disease assets to concentrate its resources entirely on its late-stage oncology portfolio. This sharpened focus allowed the company to advance its key cancer treatments through the demanding clinical trial process. The pivotal moment in the ChemGenex playbook arrived in March 2011. After navigating the ups and downs of drug development, including a setback from the US FDA, the company received a takeover offer from the US-based biopharmaceutical firm, Cephalon. Cephalon, which already held a significant stake in the company, offered to acquire the remainder of ChemGenex for approximately $163 million, a deal valued at about $231 million in total. The board of ChemGenex unanimously supported the offer, which represented a major premium on its share price. The acquisition was completed, and ChemGenex was delisted in July 2011, marking the end of its journey as an independent entity.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
6
Open positions
None listed
Dealroom signal
75.1/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Mar 2011 $225M $225M Cephalon —
SERIES A✓Equity / VC Mar 2007 $21M $84M Alta Partners · GBS Venture Partners —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

ChemGenex Pharmaceuticals website traffic

Latest recorded traffic for ChemGenex Pharmaceuticals is 0 monthly website visits, down 100% over the last three months. ChemGenex Pharmaceuticals's team grew 20% over the past year.

Latest monthly visits0 3-month web change-100% 1-year team growth+20%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

ChemGenex Pharmaceuticals in the Geelong ecosystem

Live from Dealroom

The ChemGenex Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Alta Partners
  • GBS Venture Partners

Other known investors1 additional known investor

  • Cephalon
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇮🇳 India100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about ChemGenex Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ChemGenex Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.